DPP4 inhibitors are currently being used as part of the medical management of T2DM in humans, as they improve glycaemic control through increasing GLP-1 concentrations, thus stimulating pancreatic insulin secretion, inhibiting glucagon release and reducing appetite [46]. Here, DPP4 is linked to type 2 diabetes mellitus.